MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F64

Bromocriptine Use and the Risk of Valvular Heart Disease

Identifieur interne : 000F64 ( PascalFrancis/Corpus ); précédent : 000F63; suivant : 000F65

Bromocriptine Use and the Risk of Valvular Heart Disease

Auteurs : Louis C. S. Tan ; Kenneth K. C. Ng ; Wing-Lok Au ; Raymond K. K. Lee ; Yiong-Huak Chan ; Nigel C. K. Tan

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0136792

Descripteurs français

Pascal (Inist)
- Cardiopathie valvulaire, Pathologie du système nerveux, Bromocriptine, Facteur risque, Récepteur sérotoninergique 5-HT2, Ergotamine, Pergolide, Stimulant dopaminergique.

English descriptors

KwdEn :
- 5-HT2 Serotonine receptor, Bromocriptine, Cardiac valvular disease, Dopamine agonist, Ergotamine, Nervous system diseases, Pergolide, Risk factor.

Abstract

It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT_2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Bromocriptine Use and the Risk of Valvular Heart Disease`
A11	`01`	`1`		`@1 TAN (Louis C. S.)`
A11	`02`	`1`		`@1 NG (Kenneth K. C.)`
A11	`03`	`1`		`@1 AU (Wing-Lok)`
A11	`04`	`1`		`@1 LEE (Raymond K. K.)`
A11	`05`	`1`		`@1 CHAN (Yiong-Huak)`
A11	`06`	`1`		`@1 TAN (Nigel C. K.)`
A14	`01`			`@1 Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute @3 SGP @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 USA National Parkinson Foundation Centre of Excellence @3 USA @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 Department of Neurology, National Neuroscience Institute @3 SGP @Z 1 aut. @Z 3 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Cardiology, Tan Tock Seng Hospital @3 SGP @Z 2 aut. @Z 4 aut.`
A14	`05`			`@1 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore @3 SGP @Z 5 aut.`
A20				`@1 344-349`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186999840040`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 09-0136792`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT_2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Cardiopathie valvulaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Cardiac valvular disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Cardiopatía valvular @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Bromocriptine @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Bromocriptine @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Bromocriptina @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Facteur risque @5 10`
C03	`04`	`X`	`ENG`	`@0 Risk factor @5 10`
C03	`04`	`X`	`SPA`	`@0 Factor riesgo @5 10`
C03	`05`	`X`	`FRE`	`@0 Récepteur sérotoninergique 5-HT2 @5 11`
C03	`05`	`X`	`ENG`	`@0 5-HT2 Serotonine receptor @5 11`
C03	`05`	`X`	`SPA`	`@0 Receptor serotoninérgico 5-HT2 @5 11`
C03	`06`	`X`	`FRE`	`@0 Ergotamine @2 NK @2 FR @5 12`
C03	`06`	`X`	`ENG`	`@0 Ergotamine @2 NK @2 FR @5 12`
C03	`06`	`X`	`SPA`	`@0 Ergotamina @2 NK @2 FR @5 12`
C03	`07`	`X`	`FRE`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`07`	`X`	`ENG`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`07`	`X`	`SPA`	`@0 Pergolida @2 NK @2 FR @5 13`
C03	`08`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 14`
C03	`08`	`X`	`ENG`	`@0 Dopamine agonist @5 14`
C03	`08`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 14`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
N21				`@1 096`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0136792 INIST
ET :	Bromocriptine Use and the Risk of Valvular Heart Disease
AU :	TAN (Louis C. S.); NG (Kenneth K. C.); AU (Wing-Lok); LEE (Raymond K. K.); CHAN (Yiong-Huak); TAN (Nigel C. K.)
AF :	Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute/Singapour (1 aut., 3 aut.); USA National Parkinson Foundation Centre of Excellence/Etats-Unis (1 aut., 3 aut.); Department of Neurology, National Neuroscience Institute/Singapour (1 aut., 3 aut., 6 aut.); Department of Cardiology, Tan Tock Seng Hospital/Singapour (2 aut., 4 aut.); Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore/Singapour (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 344-349; Bibl. 30 ref.
LA :	Anglais
EA :	It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT_2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.
CC :	002B17; 002B17G
FD :	Cardiopathie valvulaire; Pathologie du système nerveux; Bromocriptine; Facteur risque; Récepteur sérotoninergique 5-HT2; Ergotamine; Pergolide; Stimulant dopaminergique
FG :	Pathologie de l'appareil circulatoire
ED :	Cardiac valvular disease; Nervous system diseases; Bromocriptine; Risk factor; 5-HT2 Serotonine receptor; Ergotamine; Pergolide; Dopamine agonist
EG :	Cardiovascular disease
SD :	Cardiopatía valvular; Sistema nervioso patología; Bromocriptina; Factor riesgo; Receptor serotoninérgico 5-HT2; Ergotamina; Pergolida; Estimulante dopaminérgico
LO :	INIST-20953.354000186999840040
ID :	09-0136792

Links to Exploration step

Pascal:09-0136792

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Bromocriptine Use and the Risk of Valvular Heart Disease</title>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name>
<affiliation><inist:fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0136792</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0136792 INIST</idno>
<idno type="RBID">Pascal:09-0136792</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F64</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Bromocriptine Use and the Risk of Valvular Heart Disease</title>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name>
<affiliation><inist:fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT2 Serotonine receptor</term>
<term>Bromocriptine</term>
<term>Cardiac valvular disease</term>
<term>Dopamine agonist</term>
<term>Ergotamine</term>
<term>Nervous system diseases</term>
<term>Pergolide</term>
<term>Risk factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cardiopathie valvulaire</term>
<term>Pathologie du   système nerveux</term>
<term>Bromocriptine</term>
<term>Facteur risque</term>
<term>Récepteur sérotoninergique 5-HT2</term>
<term>Ergotamine</term>
<term>Pergolide</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT<sub>2B</sub>
 activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Bromocriptine Use and the Risk of Valvular Heart Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TAN (Louis C. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NG (Kenneth K. C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AU (Wing-Lok)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEE (Raymond K. K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHAN (Yiong-Huak)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TAN (Nigel C. K.)</s1>
</fA11>
<fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>344-349</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186999840040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0136792</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT<sub>2B</sub>
 activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cardiopathie valvulaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cardiac valvular disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cardiopatía valvular</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur sérotoninergique 5-HT2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>5-HT2 Serotonine receptor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor serotoninérgico 5-HT2</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ergotamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ergotamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ergotamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pergolida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>096</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0136792 INIST</NO>
<ET>Bromocriptine Use and the Risk of Valvular Heart Disease</ET>
<AU>TAN (Louis C. S.); NG (Kenneth K. C.); AU (Wing-Lok); LEE (Raymond K. K.); CHAN (Yiong-Huak); TAN (Nigel C. K.)</AU>
<AF>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute/Singapour (1 aut., 3 aut.); USA National Parkinson Foundation Centre of Excellence/Etats-Unis (1 aut., 3 aut.); Department of Neurology, National Neuroscience Institute/Singapour (1 aut., 3 aut., 6 aut.); Department of Cardiology, Tan Tock Seng Hospital/Singapour (2 aut., 4 aut.); Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore/Singapour (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 344-349; Bibl. 30 ref.</SO>
<LA>Anglais</LA>
<EA>It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT<sub>2B</sub>
 activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</EA>
<CC>002B17; 002B17G</CC>
<FD>Cardiopathie valvulaire; Pathologie du   système nerveux; Bromocriptine; Facteur risque; Récepteur sérotoninergique 5-HT2; Ergotamine; Pergolide; Stimulant dopaminergique</FD>
<FG>Pathologie de l'appareil circulatoire</FG>
<ED>Cardiac valvular disease; Nervous system diseases; Bromocriptine; Risk factor; 5-HT2 Serotonine receptor; Ergotamine; Pergolide; Dopamine agonist</ED>
<EG>Cardiovascular disease</EG>
<SD>Cardiopatía valvular; Sistema nervioso patología; Bromocriptina; Factor riesgo; Receptor serotoninérgico 5-HT2; Ergotamina; Pergolida; Estimulante dopaminérgico</SD>
<LO>INIST-20953.354000186999840040</LO>
<ID>09-0136792</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F64 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F64 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0136792
   |texte=   Bromocriptine Use and the Risk of Valvular Heart Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Bromocriptine Use and the Risk of Valvular Heart Disease

Bromocriptine Use and the Risk of Valvular Heart Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri